149 related articles for article (PubMed ID: 30099213)
1. Novel approaches for improving stability of cysteamine formulations.
Dixon P; Powell K; Chauhan A
Int J Pharm; 2018 Oct; 549(1-2):466-475. PubMed ID: 30099213
[TBL] [Abstract][Full Text] [Related]
2. In vitro drug release and in vivo safety of vitamin E and cysteamine loaded contact lenses.
Dixon P; Fentzke RC; Bhattacharya A; Konar A; Hazra S; Chauhan A
Int J Pharm; 2018 Jun; 544(2):380-391. PubMed ID: 29217475
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses.
Hsu KH; Fentzke RC; Chauhan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):531-40. PubMed ID: 23665502
[TBL] [Abstract][Full Text] [Related]
4. [1H-NMR spectroscopic study of cysteamine eyedrops].
Gräf M; Kalinowski HO
Klin Monbl Augenheilkd; 1995 Apr; 206(4):262-5. PubMed ID: 7791287
[TBL] [Abstract][Full Text] [Related]
5. Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations.
Martín-Sabroso C; Alonso-González M; Fernández-Carballido A; Aparicio-Blanco J; Córdoba-Díaz D; Navarro-García F; Córdoba-Díaz M; Torres-Suárez AI
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056058
[TBL] [Abstract][Full Text] [Related]
6. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of topical cysteamine in nephropathic cystinosis.
Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
[TBL] [Abstract][Full Text] [Related]
8. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
[TBL] [Abstract][Full Text] [Related]
10.
Ozdemir HB; Özmen MC; Aktas Z; Hasanreisoglu M
Indian J Ophthalmol; 2019 Jan; 67(1):153-155. PubMed ID: 30574930
[TBL] [Abstract][Full Text] [Related]
11. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.
Castro-Balado A; Bandín-Vilar E; Cuartero-Martínez A; García-Quintanilla L; Hermelo-Vidal G; García-Otero X; Rodríguez-Martínez L; Mateos J; Hernández-Blanco M; Aguiar P; Zarra-Ferro I; González-Barcia M; Mondelo-García C; Otero-Espinar FJ; Fernández-Ferreiro A
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297629
[TBL] [Abstract][Full Text] [Related]
12. [Ocular treatment of cystinosis with eye drop containing cysteamine].
Csorba A; Maka E; Szabó A; Kelen K; Reusz G; Nagy ZZ
Orv Hetil; 2022 May; 163(21):846-852. PubMed ID: 35598215
[TBL] [Abstract][Full Text] [Related]
13. Gel formulations for treatment of the ophthalmic complications in cystinosis.
Buchan B; Kay G; Heneghan A; Matthews KH; Cairns D
Int J Pharm; 2010 Jun; 392(1-2):192-7. PubMed ID: 20382212
[TBL] [Abstract][Full Text] [Related]
14. Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis.
McKenzie B; Kay G; Matthews KH; Knott R; Cairns D
Int J Pharm; 2016 Dec; 515(1-2):575-582. PubMed ID: 27771488
[TBL] [Abstract][Full Text] [Related]
15. Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions.
Damian F; Fabian J; Friend DR; Kiser PF
Int J Pharm; 2010 Aug; 396(1-2):1-10. PubMed ID: 20510342
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis.
Kaur S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bhattacharyya J; Kaur H; Kumar S; Medhi B; Ram J; Das D; Avti P; Prakash A; Singh R; Bhattacharyya A
Am J Ophthalmol; 2021 Mar; 223():275-285. PubMed ID: 32888903
[TBL] [Abstract][Full Text] [Related]
17. Ocular biodistribution of cysteamine delivered by a sustained release microsphere/thermoresponsive gel eyedrop.
Jimenez J; Resnick JL; Chaudhry AB; Gertsman I; Nischal KK; DiLeo MV
Int J Pharm; 2022 Aug; 624():121992. PubMed ID: 35809831
[TBL] [Abstract][Full Text] [Related]
18. Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.
Reda A; Van Schepdael A; Adams E; Paul P; Devolder D; Elmonem MA; Veys K; Casteels I; van den Heuvel L; Levtchenko E
JIMD Rep; 2018; 42():47-51. PubMed ID: 29214524
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
[TBL] [Abstract][Full Text] [Related]
20. A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability.
Jimenez J; Washington MA; Resnick JL; Nischal KK; Fedorchak MV
Drug Deliv Transl Res; 2021 Oct; 11(5):2224-2238. PubMed ID: 33543397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
